926 related articles for article (PubMed ID: 19783775)
1. Allogenic stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension.
Umar S; de Visser YP; Steendijk P; Schutte CI; Laghmani el H; Wagenaar GT; Bax WH; Mantikou E; Pijnappels DA; Atsma DE; Schalij MJ; van der Wall EE; van der Laarse A
Am J Physiol Heart Circ Physiol; 2009 Nov; 297(5):H1606-16. PubMed ID: 19783775
[TBL] [Abstract][Full Text] [Related]
2. Let-7a-transfected mesenchymal stem cells ameliorate monocrotaline-induced pulmonary hypertension by suppressing pulmonary artery smooth muscle cell growth through STAT3-BMPR2 signaling.
Cheng G; Wang X; Li Y; He L
Stem Cell Res Ther; 2017 Feb; 8(1):34. PubMed ID: 28187784
[TBL] [Abstract][Full Text] [Related]
3. Copaiba Oil Attenuates Right Ventricular Remodeling by Decreasing Myocardial Apoptotic Signaling in Monocrotaline-Induced Rats.
Campos-Carraro C; Turck P; de Lima-Seolin BG; Tavares AMV; Dos Santos Lacerda D; Corssac GB; Teixeira RB; Hickmann A; Llesuy S; da Rosa Araujo AS; Belló-Klein A
J Cardiovasc Pharmacol; 2018 Nov; 72(5):214-221. PubMed ID: 30212415
[TBL] [Abstract][Full Text] [Related]
4. Characterization of right ventricular function after monocrotaline-induced pulmonary hypertension in the intact rat.
Hessel MH; Steendijk P; den Adel B; Schutte CI; van der Laarse A
Am J Physiol Heart Circ Physiol; 2006 Nov; 291(5):H2424-30. PubMed ID: 16731643
[TBL] [Abstract][Full Text] [Related]
5. Beneficial effects of mesenchymal stem cell delivery via a novel cardiac bioscaffold on right ventricles of pulmonary arterial hypertensive rats.
Schmuck EG; Hacker TA; Schreier DA; Chesler NC; Wang Z
Am J Physiol Heart Circ Physiol; 2019 May; 316(5):H1005-H1013. PubMed ID: 30822119
[TBL] [Abstract][Full Text] [Related]
6. Soluble guanylate cyclase stimulator, trans-4-methoxy-β-nitrostyrene, has a beneficial effect in monocrotaline-induced pulmonary arterial hypertension in rats.
Gonzaga-Costa K; Vasconcelos-Silva AA; Rodrigues-Silva MJ; Rebouça CDSM; Duarte GP; Borges RS; Magalhães PJC; Lahlou S
Eur J Pharmacol; 2021 Apr; 897():173948. PubMed ID: 33609564
[TBL] [Abstract][Full Text] [Related]
7. Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension.
Adão R; Mendes-Ferreira P; Santos-Ribeiro D; Maia-Rocha C; Pimentel LD; Monteiro-Pinto C; Mulvaney EP; Reid HM; Kinsella BT; Potus F; Breuils-Bonnet S; Rademaker MT; Provencher S; Bonnet S; Leite-Moreira AF; Brás-Silva C
Cardiovasc Res; 2018 Jul; 114(8):1165-1177. PubMed ID: 29584808
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary Artery Hypertension Model in Rats by Monocrotaline Administration.
Bueno-Beti C; Sassi Y; Hajjar RJ; Hadri L
Methods Mol Biol; 2018; 1816():233-241. PubMed ID: 29987824
[TBL] [Abstract][Full Text] [Related]
9. Intralipid prevents and rescues fatal pulmonary arterial hypertension and right ventricular failure in rats.
Umar S; Nadadur RD; Li J; Maltese F; Partownavid P; van der Laarse A; Eghbali M
Hypertension; 2011 Sep; 58(3):512-8. PubMed ID: 21747043
[TBL] [Abstract][Full Text] [Related]
10. Sulforaphane Improves Redox Homeostasis and Right Ventricular Contractility in a Model of Pulmonary Hypertension.
Conzatti A; Colombo R; Siqueira R; Campos-Carraro C; Turck P; Luz de Castro A; Belló-Klein A; Sander da Rosa Araujo A
J Cardiovasc Pharmacol; 2024 Jun; 83(6):612-620. PubMed ID: 38547510
[TBL] [Abstract][Full Text] [Related]
11. Colchicine Depolymerizes Microtubules, Increases Junctophilin-2, and Improves Right Ventricular Function in Experimental Pulmonary Arterial Hypertension.
Prins KW; Tian L; Wu D; Thenappan T; Metzger JM; Archer SL
J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28566298
[TBL] [Abstract][Full Text] [Related]
12. Increased in vivo mitochondrial oxygenation with right ventricular failure induced by pulmonary arterial hypertension: mitochondrial inhibition as driver of cardiac failure?
Balestra GM; Mik EG; Eerbeek O; Specht PA; van der Laarse WJ; Zuurbier CJ
Respir Res; 2015 Feb; 16(1):6. PubMed ID: 25645252
[TBL] [Abstract][Full Text] [Related]
13. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS
Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924
[TBL] [Abstract][Full Text] [Related]
14. Mesenchymal stromal cell therapy reduces lung inflammation and vascular remodeling and improves hemodynamics in experimental pulmonary arterial hypertension.
de Mendonça L; Felix NS; Blanco NG; Da Silva JS; Ferreira TP; Abreu SC; Cruz FF; Rocha N; Silva PM; Martins V; Capelozzi VL; Zapata-Sudo G; Rocco PRM; Silva PL
Stem Cell Res Ther; 2017 Oct; 8(1):220. PubMed ID: 28974252
[TBL] [Abstract][Full Text] [Related]
15. PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats.
Porvasnik SL; Germain S; Embury J; Gannon KS; Jacques V; Murray J; Byrne BJ; Shacham S; Al-Mousily F
J Pharmacol Exp Ther; 2010 Aug; 334(2):364-72. PubMed ID: 20430844
[TBL] [Abstract][Full Text] [Related]
16. Exosomes induce and reverse monocrotaline-induced pulmonary hypertension in mice.
Aliotta JM; Pereira M; Wen S; Dooner MS; Del Tatto M; Papa E; Goldberg LR; Baird GL; Ventetuolo CE; Quesenberry PJ; Klinger JR
Cardiovasc Res; 2016 Jun; 110(3):319-30. PubMed ID: 26980205
[TBL] [Abstract][Full Text] [Related]
17. Propylthiouracil attenuates monocrotaline-induced pulmonary arterial hypertension in rats.
Sun CK; Yuen CM; Kao YH; Chang LT; Chua S; Sheu JJ; Yen CH; Ko SF; Yip HK
Circ J; 2009 Sep; 73(9):1722-30. PubMed ID: 19602776
[TBL] [Abstract][Full Text] [Related]
18. PBI-4050 reduces pulmonary hypertension, lung fibrosis, and right ventricular dysfunction in heart failure.
Nguyen QT; Nsaibia MJ; Sirois MG; Calderone A; Tardif JC; Fen Shi Y; Ruiz M; Daneault C; Gagnon L; Grouix B; Laurin P; Dupuis J
Cardiovasc Res; 2020 Jan; 116(1):171-182. PubMed ID: 30753422
[TBL] [Abstract][Full Text] [Related]
19. Pathophysiology of infantile pulmonary arterial hypertension induced by monocrotaline.
Dias-Neto M; Luísa-Neves A; Pinho S; Gonçalves N; Mendes M; Eloy C; Lopes JM; Gonçalves D; Ferreira-Pinto M; Leite-Moreira AF; Henriques-Coelho T
Pediatr Cardiol; 2015 Jun; 36(5):1000-13. PubMed ID: 25608696
[TBL] [Abstract][Full Text] [Related]
20. Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension.
Rocchetti M; Sala L; Rizzetto R; Staszewsky LI; Alemanni M; Zambelli V; Russo I; Barile L; Cornaghi L; Altomare C; Ronchi C; Mostacciuolo G; Lucchetti J; Gobbi M; Latini R; Zaza A
Cardiovasc Res; 2014 Oct; 104(1):37-48. PubMed ID: 25139747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
